• University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation
• Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain
• Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)
  
   

BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the University of Arizona College of Medicine - Phoenix as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The groundbreaking CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.